214 related articles for article (PubMed ID: 29311344)
41. Devices to decrease stroke risk.
Tuzcu EM
J Invasive Cardiol; 2004 Jul; 16(7 Suppl):54S-58S. PubMed ID: 23573575
[TBL] [Abstract][Full Text] [Related]
42. Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe--a multicentric evaluation.
Luger S; Hohmann C; Kraft P; Halmer R; Gunreben I; Neumann-Haefelin T; Kleinschnitz C; Walter S; Haripyan V; Steinmetz H; Foerch C; Pfeilschifter W
Int J Stroke; 2014 Jul; 9(5):569-75. PubMed ID: 24828272
[TBL] [Abstract][Full Text] [Related]
43. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis.
Almekhlafi MA; Wilton SB; Rabi DM; Ghali WA; Lorenzetti DL; Hill MD
Neurology; 2009 Jul; 73(2):89-97. PubMed ID: 19439720
[TBL] [Abstract][Full Text] [Related]
44. RoPE Score as a Predictor of Recurrent Ischemic Events After Percutaneous Patent Foramen Ovale Closure.
Morais LA; Sousa L; Fiarresga A; Martins JD; Timóteo AT; Monteiro AV; Soares C; Agapito A; Pinto F; Ferreira RC
Int Heart J; 2018 Nov; 59(6):1327-1332. PubMed ID: 30305578
[TBL] [Abstract][Full Text] [Related]
45. Higher LA pressure may prevent opening of patent foramen ovale in acute ischemic stroke patients with atrial fibrillation.
Aoki J; Kimura K; Iguchi Y; Shibazaki K; Sakai K; Terasawa Y; Sakamoto Y
J Neurol Sci; 2011 May; 304(1-2):111-6. PubMed ID: 21345454
[TBL] [Abstract][Full Text] [Related]
46. [Multidisciplinary position paper on the management of patent foramen ovale in the presence of cryptogenic cerebral ischemia - Italian version 2013].
; ; ; ; ; ; ; ; Pristipino C; Anzola GP; Ballerini L; Bartorelli A; Cecconi M; Chessa M; Donti A; Gaspardone A; Neri G; Onorato E; Palareti G; Rakar S; Rigatelli G; Santoro G; Toni D; Ussia GP; Violini R; Guagliumi G; Bedogni F; Cremonesi A
G Ital Cardiol (Rome); 2013 Oct; 14(10):699-712. PubMed ID: 24121896
[TBL] [Abstract][Full Text] [Related]
47. Ischemic stroke and patent foramen ovale: risk factors and genetic profile.
Lantz M; Sjöstrand C; Kostulas K
J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):841-5. PubMed ID: 22784820
[TBL] [Abstract][Full Text] [Related]
48. [Patent foramen ovale and stroke].
Mono ML; Nedeltchev K
Fortschr Neurol Psychiatr; 2012 May; 80(5):288-99. PubMed ID: 22566139
[No Abstract] [Full Text] [Related]
49. New onset atrial fibrillation after patent foramen ovale closure.
Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
[TBL] [Abstract][Full Text] [Related]
50. Toward understanding the atrial septum in cryptogenic stroke.
Cotter PE; Martin PJ; Belham M
Int J Stroke; 2011 Oct; 6(5):445-53. PubMed ID: 21951410
[TBL] [Abstract][Full Text] [Related]
51. Proportion of acute ischaemic strokes attributable to a cardiac aetiology in an unselected young patient population: A single centre experience.
Bahl R; Kubiak M; Yusoff S; Tung H; Stirrup J; van Wyk A; Nagaratnam K; Ruparelia N
Clin Med (Lond); 2020 Mar; 20(2):174-177. PubMed ID: 32188654
[TBL] [Abstract][Full Text] [Related]
52. Brief history of patent foramen ovale and stroke.
Furlan AJ
Stroke; 2015 Feb; 46(2):e35-7. PubMed ID: 25586831
[No Abstract] [Full Text] [Related]
53. Patent foramen ovale and cryptogenic stroke.
Nakanishi K; Yoshiyama M; Homma S
Trends Cardiovasc Med; 2017 Nov; 27(8):575-581. PubMed ID: 28709812
[TBL] [Abstract][Full Text] [Related]
54. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
55. Neurologic Complications of Cardiac and Aortic Disease.
Klaas JP
Continuum (Minneap Minn); 2017 Jun; 23(3, Neurology of Systemic Disease):654-668. PubMed ID: 28570323
[TBL] [Abstract][Full Text] [Related]
56. Patent foramen ovale and cryptogenic stroke.
Jaquis J
Dimens Crit Care Nurs; 2007; 26(6):233-6. PubMed ID: 18090138
[TBL] [Abstract][Full Text] [Related]
57. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
58. Anticoagulant-Free but Dangerous: Perisurgical Consideration.
Aiba Y; Sakakibara R; Tsuyusaki Y; Kishi M; Tateno F; Ogata T; Nagao T; Terada H; Inaoka T
J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):2038-2040. PubMed ID: 28711363
[No Abstract] [Full Text] [Related]
59. Percutaneous closure of patent foramen ovale and the risk of atrial fibrillation.
Bhindi R
Catheter Cardiovasc Interv; 2010 Feb; 75(2):301; author reply 302. PubMed ID: 20049956
[No Abstract] [Full Text] [Related]
60. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
